Anthony Daniyan, MD
Leukemia Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Adult Acute and Chronic Leukemias
- Adoptive Cellular Therapy
About Me
- Assistant Attending Physician
I am a medical oncologist who cares for people who have been admitted to Memorial Hospital to be treated for leukemia. I am also a member of MSK’s Cellular Therapeutics Center. We are working to develop the next generation of a promising type of immunotherapy called CAR T cell therapy.
Read more
For as long as I can remember, I have been fascinated by the workings of cells and the immune system. These two interests converged on oncology, allowing me to focus on not only the underlying disease, but on ways to target and eradicate it through the use of immunotherapy.
When patients are in the hospital, they are often concerned about getting the most appropriate therapy for their unique disease. I try to alleviate these concerns by involving my patients in the treatment planning process and explaining the reasoning behind each approach.
After I meet with patients and their families, it’s my goal that they feel hopeful that we will help them feel better. This can mean treating their disease to cure it, and also alleviating symptoms to improve their quality of life.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Adult Acute and Chronic Leukemias
- Adoptive Cellular Therapy
Education
- MD, University of Miami Miller School of Medicine
Residencies
- Internal Medicine - NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Awards and Honors
- Mortimer J. Lacher Fellowship in Hematological Oncology, Memorial Sloan Kettering (2015)
- Young Investigator Award, Conquer Cancer Foundation of ASCO (2017)
- K12 Paul Calabresi Career Development Award for Clinical Oncology, Memorial Sloan Kettering (2017)
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Contact and Location
Dr. Daniyan sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.
Visit PubMed for a full listing of Dr. Daniyan’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Anthony Daniyan discloses the following relationships and financial interests:
-
Biolumina
Professional Services and Activities -
Caribou Biosciences, Inc.
Intellectual Property Rights -
Hierax Therapeutics, Inc.
Professional Services and Activities
-
NomoCan Pharmaceuticals LLC
Professional Services and Activities -
Syndax
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
